SCHEMBL6794467

SCHEMBL6794467

CN1CCN(C(=O)c2cc(-c3ccccc3)c3c(n2)OCCN(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C3=O)CC1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 6/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 2/20 0.41
HPGD P15428 2/20 0.41
LMNA P02545 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
ROCK2 O75116 1/20 0.39
ROCK1 Q13464 1/20 0.39
TP53 P04637 1/20 0.38
ALDH1A1 P00352 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
SIRT1 Q96EB6 1/20 0.36
TNIK Q9UKE5 1/20 0.36
EPHX2 P34913 1/20 0.36
KCNH2 Q12809 1/20 0.36
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6789811 0.92 KDM4E (0.42) SMN1; SMN2KDM4EHPGDROCK2ROCK1
SCHEMBL6795180 0.92 ROCK2 (0.40) TACR1SMN1; SMN2HPGDLMNANPC1
SCHEMBL6794230 0.88 ROCK2 (0.43) TACR1ROCK2ROCK1SIRT2SIRT1
SCHEMBL6794591 0.87 GRM2 (0.46) TACR1LMNAROCK2ROCK1SIRT2
SCHEMBL6789047 0.86 TACR1 (0.41) TACR1ROCK2ROCK1SIRT2SIRT1
SCHEMBL6797973 0.86 KDM4E (0.41) TACR1SMN1; SMN2KDM4EROCK2ROCK1
SCHEMBL6794195 0.84 ROCK2 (0.41) TACR1KDM4EROCK2ROCK1ALDH1A1
SCHEMBL4513882 0.83 ROCK2 (0.44) TACR1ROCK2ROCK1SIRT2SIRT1
SCHEMBL6794050 0.82 ROCK2 (0.44) TACR1ROCK2ROCK1SIRT2SIRT1
SCHEMBL6794992 0.82 TACR1 (0.40) TACR1HPGDLMNAROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058914-A1 Combination drugs TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-25 US disclosed
US-20040023843-A1 Preventives/remedies for emotional disorders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-02-05 US disclosed
EP-1352659-A1 COMBINATION DRUGS Takeda Chemical Industries, Ltd. (JP) 2003-10-15 EP disclosed
EP-1323429-A1 PREVENTIVES/REMEDIES FOR EMOTIONAL DISORDERS Takeda Chemical Industries, Ltd. (JP) 2003-07-02 EP disclosed
EP-1145714-A1 DRUGS Takeda Chemical Industries, Ltd. (JP) 2001-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023843-A1 Preventives/remedies for emotional disorders MTNR1A, KISS1R, MTNR1B TACR1 12/4885SMN1; SMN2 2817/4885KDM4E 2229/4885
US-20040058914-A1 Combination drugs CHRNA1, CHRNA2, CHRM2 TACR1 39/4885SMN1; SMN2 1564/4885KDM4E 2987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.